In stage III unresectable NSCLC after concurrent chemoradiation, tiragolumab plus atezolizumab did not improve IRF-assessed PFS vs durvalumab in 419 PD-L1-positive patients (median 19.4 vs 16.6 months; HR 0.96, P=0.76). No overall survival difference.
RCTn = 829
Wakelee et al. SKYSCRAPER-03: a phase III study of tiragolumab plus atezolizumab versus durvalumab in locally advanced, unresectable, stage III NSCLC after platinum-based concurrent chemoradiation